A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be value-enhancing add-ons to the target company, specifically in the GI space.
Alacrita conducted a comprehensive search of late stage and commercial assets that had a good fit with the target company's therapeutic focus. We generated a long list of potential opportunities and, based on iterative discussions with our PE client, we filtered the database to yield a short list of 20 potential opportunities that represented the best combination of fit and potential availability. In addition, we generated a long list of other opportunities in adjacent areas for further consideration.
We have deep experience on both the buy and sell-side, and work with our clients to ensure that partnership, licensing and investment decisions are taken with confidence, along with clear alignment between transaction price and asset value.